{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:59:35Z","timestamp":1790913575200,"version":"4.1.0"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Autoimmune diseases are a group of diseases in which the body\u2019s immune system misrecognizes its own antigens resulting in an abnormal immune response, which can lead to pathological damage to or abnormal functioning of its own tissues. Current treatments are mainly hormones and broad-spectrum immunosuppressants, but these can lead to a decline in the patient\u2019s immunity. Chimeric antigen receptor T (CAR-T) Cell therapy has emerged, and now the structure of CAR has changed from first generation to fourth generation of CAR. The significant achievement of CAR-T therapy to B-cell leukemia has also inspired the treatment of autoimmune diseases, and by investigating the mechanisms of different autoimmune diseases, different designs of CAR-T can be used to specifically treat autoimmune diseases. In this review, we will discuss the therapeutic strategies of CAR-T cells in different autoimmune diseases and the limitations of the treatment.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1533254","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T07:11:38Z","timestamp":1741072298000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Advance in chimeric antigen receptor T therapy in autoimmune diseases"],"prefix":"10.3389","volume":"16","author":[{"given":"Xiaolan","family":"Ji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianling","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.97","article-title":"Engineered T cells: the promise and challenges of cancer immunotherapy","volume":"16","author":"Fesnak","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross G","year":"1989","journal-title":"Sci U.S.A"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00849","article-title":"CAR T-cell therapy for B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia: clinical trials and real-world experiences","volume":"10","author":"Vitale","year":"2020","journal-title":"Front Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1089\/hgtb.2016.153","article-title":"CAR T-cell therapy: progress and prospects","volume":"28","author":"Wilkins","year":"2017","journal-title":"Hum Gene Ther Methods"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: the fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.609421","article-title":"The BCMA-targeted fourth-generation CAR-T cells secreting IL-7 and CCL19 for therapy of refractory\/recurrent multiple myeloma","volume":"12","author":"Duan","year":"2021","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1018786","article-title":"CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil","volume":"13","author":"Nasiri","year":"2022","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4478","article-title":"A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3760\/cma.j.issn.1673-4912.2011.02.003","article-title":"Application of blood purification technique in autoimmune disease","volume":"18","author":"Wu","year":"2011","journal-title":"Chin Pediatr Emergency Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2013.11.013","article-title":"Contributions of B cells to lupus pathogenesis","volume":"62","author":"Sang","year":"2014","journal-title":"Mol Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-021-01470-1","article-title":"Are chimeric antigen receptor T cells (CAR-T cells) the future in immunotherapy for autoimmune diseases","volume":"70","author":"Santamaria-Alza","year":"2021","journal-title":"Inflammation Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - A case series with follow-up","volume":"390","author":"Muller","year":"2024","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0472-1","article-title":"Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus","volume":"18","author":"Jin","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00194-1","article-title":"Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study","volume":"22","author":"Granit","year":"2023","journal-title":"Lancet Neurol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2018.08.004","article-title":"Chimeric antigen receptor (CAR) T cells targeting a pathogenic MHC class II:peptide complex modulate the progression of autoimmune diabetes","volume":"96","author":"Zhang","year":"2019","journal-title":"J Autoimmun"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.01.049","article-title":"Amelioration of colitis by genetically engineered murine regulatory T cells redirected by antigen-specific chimeric receptor","volume":"136","author":"Elinav","year":"2009","journal-title":"Gastroenterology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.661875","article-title":"Antigen-specific regulatory T cell therapy in autoimmune diseases and transplantation","volume":"12","author":"Selck","year":"2021","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.41","article-title":"Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells","volume":"22","author":"Blat","year":"2014","journal-title":"Mol Ther"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01125","article-title":"Chimeric antigen receptor-redirected regulatory T cells suppress experimental allergic airway inflammation, a model of asthma","volume":"8","author":"Skuljec","year":"2017","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02231","article-title":"Chimeric antigen receptors based on low affinity mutants of fcepsilonRI re-direct T cell specificity to cells expressing membrane igE","volume":"9","author":"Ward","year":"2018","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0907396106","article-title":"Adoptive therapy with redirect-ted primary regulatory T cells results in antigen-specific suppression of arthritisa","volume":"106","author":"Wright","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201948470","article-title":"Regulatory T cell metabolism at the intersection between autoimmune diseases and cancer","volume":"50","author":"Kurniawan","year":"2020","journal-title":"Eur J Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"106378","DOI":"10.1016\/j.intimp.2020.106378","article-title":"The relationship between TIGIT(+) regulatory T cells and autoimmune disease","volume":"83","author":"Lee","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-022-01637-z","article-title":"Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells","volume":"41","author":"Oh","year":"2023","journal-title":"Nat Biotechnol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2011.06.009","article-title":"Lupus nephritis: role of antinucleosome autoantibodies","volume":"31","author":"van der Vlag","year":"2011","journal-title":"Semin Nephrol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn113694-20221017-00767","article-title":"Expert consensus on laboratory diagnosis of myasthenia gravis autoantibodies 2022","volume":"56","author":"Shi","year":"2023","journal-title":"Chin J Neurol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-020-00092-2","article-title":"B cell depletion therapies in autoimmune disease: advances and mechanistic insights","volume":"20","author":"Lee","year":"2021","journal-title":"Nat Rev Drug Discovery"},{"key":"B33","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12935-021-01763-9","article-title":"Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer","volume":"21","author":"Jin","year":"2021","journal-title":"Cancer Cell Int"},{"key":"B34","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s12016-018-8721-0","article-title":"Regulatory T cell plasticity and stability and autoimmune diseases","volume":"58","author":"Qiu","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibtech.2019.12.009","article-title":"Toward an optimized process for clinical manufacturing of CAR-treg cell therapy","volume":"38","author":"Fritsche","year":"2020","journal-title":"Trends Biotechnol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"109685","DOI":"10.1016\/j.biopha.2019.109685","article-title":"Chimeric antigen receptor -T cell therapy: Applications and challenges in treatment of allergy and asthma","volume":"123","author":"Esmaeilzadeh","year":"2020","journal-title":"BioMed Pharmacother"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/art.41812","article-title":"Is there a place for chimeric antigen receptor-T cells in the treatment of chronic autoimmune rheumatic diseases","volume":"73","author":"Orvain","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.2018.1412.issue-1","article-title":"Mechanisms underlying B cell immune dysregulation and autoantibody production in MuSK myasthenia gravis","volume":"1412","author":"Stathopoulos","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2020.610964","article-title":"The neuromuscular junction in health and disease: molecular mechanisms governing synaptic formation and homeostasis","volume":"13","author":"Rodriguez Cruz","year":"2020","journal-title":"Front Mol Neurosci"},{"key":"B40","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/acr.21664","article-title":"American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis","volume":"64","author":"Hahn","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.reuma.2010.11.001","article-title":"Multiethnic lupus cohorts: What have they taught us","volume":"7","author":"Alarc\u00f3n","year":"2011","journal-title":"Reumatolog\u00eda Cl\u00ednica (English Edition)"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel039","article-title":"An assessment of renal failure in an SLE cohort with special reference to ethnicity, over a 25-year period","volume":"45","author":"Adler","year":"2006","journal-title":"Rheumatol (Oxford)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0123572","article-title":"Anti-C1q antibodies as a follow-up marker in SLE patients","volume":"10","author":"Bock","year":"2015","journal-title":"PloS One"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1080\/15321819.2021.1895215","article-title":"High frequency of concurrent anti-C1q and anti-dsDNA but not anti-C3b antibodies in patients with Lupus Nephritis","volume":"42","author":"Kianmehr","year":"2021","journal-title":"J Immunoassay Immunochem"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25084226","article-title":"Precise targeting of autoantigen-specific B cells in lupus nephritis with chimeric autoantibody receptor T cells","volume":"25","author":"Sole","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.927153","article-title":"CAR-T cell therapy in hematological Malignancies: current opportunities and challenges","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-022-00537-5","article-title":"CAR-based therapies: opportunities for immuno-medicine beyond cancer","volume":"4","author":"Aghajanian","year":"2022","journal-title":"Nat Metab"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1533254\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T07:11:41Z","timestamp":1741072301000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1533254\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,4]]},"references-count":47,"alternative-id":["10.3389\/fimmu.2025.1533254"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1533254","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,4]]},"article-number":"1533254"}}